Pharmaceutical giants like Johnson & Johnson, Merck, and Eli Lilly are increasingly focusing on upskilling their workforce in generative AI. J&J has trained over 56,000 employees, emphasizing the significance of both specialized job skills and fluency in AI technology. This initiative aims to harness AI's potential to accelerate drug development processes, improve regulatory compliance, and refine clinical trial patient selection. As AI becomes pivotal in the industry, the skills required for new roles are shifting, with a reduced emphasis on traditional biology and chemistry knowledge.
Pharmaceutical companies are increasingly focusing on AI upskilling, with J&J training over 56,000 employees in generative AI to enhance drug development efficiency.
AI is revolutionizing drug development, facilitating faster identification of compounds, streamlining regulatory compliance, and optimizing clinical trial patient selection.
Collection
[
|
...
]